Total RNA from cell lines and CD4-positive cells were extracted using the Trizol reagent (Ambion), according to the manufacturer's instructions. MiRNAs were reverse transcribed using the Universal cDNA Synthesis Kit II (Exiqon). The expression of miR-125b, RNU1A1 and SNORD44 (used as reference genes) was measured by quantitative PCR using a specific Exiqon PCR primer set (Supplementary Table 1 ) and a SYBR qPCR Premix Ex Taq (Tli RNaseH Plus) Kit from Takara. Messenger RNAs (mRNAs) were reverse transcribed using a SuperScript II Reverse Transcriptase (Invitrogen), according to the manufacturer's recommendations. Data are presented as relative quantities of target RNA. The high-throughput qPCR analysis method used for measuring BAK1 expression was performed using the primers listed in Table  S1 and the BioMark 96 × 96 gene expression platform, according to the manufacturer's instructions (Fluidigm).
MiRNA and siRNA transfections
0.5 nmol of si-RNAs or microRNA mimics (miR125b-5p mimic microRNA, mirVana hsa-miR125 MC10148, and negative control mimic mirVana control AM17110; Thermo Fisher) were electro-transfected using the Biorad Gene pulser (at 250 V and 950 µF) into 5.10 6 ALCL cells resuspended in 400 µl of serum-free medium. Immediately after transfection cells were transferred into 5 ml pre-warmed complete RPMI-1640 medium. The si-RNA sequences are listed in Supplementary Table 1 .
MiRNA expression microarray
Microarray experiments were carried out using 1-color hybridizations on a human miRNA microarray (V3, 8 × 15K) (Agilent, Cat No: G4471A-021827): one glass slide formatted with eight high-definition 15 K arrays, based on the Sanger miRbase (release 12.0), with 866 human and 89 human viral miRNA probes represented. The mean normalized signal from the biological replicates was used for comparative expression analysis. A paired t-test with Benjamini-Hochberg correction (P value ≤ 0.05) was used to identify miRNAs differentially-expressed between tumor and benign tissues. The fold change in expression between tumor and benign samples was calculated from the normalized values.
DNA bisulfite treatment and bisulfite pyrosequencing
Genomic DNA (gDNA) was extracted using either the QIAamp DNA Mini Kit (Qiagen) or the Allprep DNA/ RNA/miRNA Kit (Qiagen), according to the manufacturer's instructions. Bisulfite conversion was then conducted with 500 ng gDNA, using the MethylEdge Bisulfite Conversion System (Promega). Two regions of interest in the miR125-b promoters, containing 7 and 6 CpGs respectively, were amplified by PCR (PCR PyroMark Kit, Qiagen), with specific primers designed by the PyroMark Assay Design software (Qiagen), one of which was biotinylated for subsequent binding of the PCR products to streptavidin-coated sepharose beads. Methylation analysis was performed on the PyroMark Q24 Pyrosequencing System (Qiagen) using specific sequencing primers (Supplementary Table 1 ) and products and protocols supplied by the manufacturer.
Protein extraction and Western blotting analyses
Total cell lysates were prepared in RIPA buffer (20 mM Tris-HCl, 150 mM NaCl, 4 mM EDTA, 0.5% Triton X100 and 0.2% SDS). Protein concentrations were determined using a Bradford assay (Biorad). The primary antibodies used are listed in Supplementary  Table 2 . HRP-conjugated anti-mouse (Jackson Immuno Research) or anti-rabbit antibodies (Cell Signaling) were used as secondary antibodies. Densitometric analysis was performed using GeneTools software from Syngene.
Cell proliferation assay
The CellTiter 96AQueus One Solution provided by Promega was used to assess cell proliferation/survival, according to the manufacturer's instructions.
Apoptosis luminescent assay
The Caspase-Glo ® 3/7 Assay Kit provided by Promega was used to assess cell apoptosis, according to the manufacturer's instructions.
Annexin V/propidium iodide (PI) double staining assay
Cells were harvested and incubated with recombinant annexin V-pacific blue at a final concentration of 1 g/ml for 5 min at room temperature. Just before analysis by flow cytometry, PI was added to all samples to a final concentration of 10 g/ml. The percentage of cells annexin V positive is indicated.
Supplementary Figure 1: NPM-ALK represses the expression of miR-125b in ALCL human and mouse models. (A)
Assessment of miR-125b expression by qRT-PCR in wild type mice (WT, n = 6) or NPM-ALK transgenic mice containing a Tet-OFF system treated (+) or not (-) with crizotinib (n = 4). SNORD202 expression served as the internal control, and the relative ratio of mmumiR-125b expression was expressed as 2 -ΔΔCt relative to WT mice. (B and C) Protein levels of NPM-ALK, p-NPM-ALK and GAPDH were assessed by western blotting in KARPAS-299 and COST cells treated or not (PBS) with crizotinib (Crizo) (B) or transfected with either an irrelevant siRNA as the negative control (si-CTL) or an siRNA targeting ALK mRNA (si-ALK) (C). Data represent means ± SEM (bars) from 3 independent experiments. * P < 0.05 and *** P < 0.0001; unpaired 2-tailed Student's t test. 
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